Clinical trial with escalating doses of the antiepidermal growth factor receptor humanized monoclonal antibody EMD 72 000 in patients with advanced squamous cell carcinoma of the larynx and hypopharynx - Bier, H; Hoffmann, T; Hauser, U; Wink, M; Ochler, M; Kovar, A; Müser, M; Knecht, R (Cancer Chemother Pharmacol, 2001)